Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia

Table 5 Mean change in SF-12 physical and mental component summary scores among patients switched to lurasidone

	Parameter	All patients	Sedating	Non-sedating
	Parameter	(N = 235)*	(n = 83)	(n = 152)
Physical component summary	Baseline (SD)	47.1 (10.1)	47.1 (10.4)	47.1 (10.0)
	LOCF (SD)	47.0 (9.8)	46.8 (9.6)	47.1 (9.9)
	Mean change (SD)	-0.2 (8.5)	-0.3 (8.2)	-0.2 (8.7)
	p-value	0.414	0.513	0.556
Mental component summary	Baseline (SD)	41.4 (11.4)	40.1 (11.6)	42.1 (11.2)
	LOCF (SD)	45.2 (11.1)	44.2 (12.5)	45.8 (10.2)
	Mean change (SD)	3.7 (11.5)	3.7 (13.3)	3.7 (10.4)
	p-value	< 0.001	0.079	< 0.001

*Patients eligible for evaluation in the analysis (N = 235) had non-missing values at baseline and ≥1 post-baseline value at study endpoint (LOCF) for any SF-12 items; n values may not sum to 235 due to missing data.
Note: preswitch sedating medications include quetiapine and olanzapine; preswitch non-sedating medications include risperidone, aripiprazole, and ziprasidone.

ISSN: 1471-244X